14th Annual Lung Cancer Symposium

Thursday, March 12, 2026, 7:00 AM - Friday, March 13, 2026, 5:00 PM, The Warwick Hotel, Philadelphia, PA


AMA PRA Category 1 Credits™ (15.00 hours), AAPA Category 1 CME Credits (15.00 hours), AARC: American Association for Respiratory Care (15.00 hours), ABIM MOC Part 2 (15.00 hours), ABS CC (15.00 hours), ANCC Contact Hour(s) (15.00 hours), Non-Physician Attendance (15.00 hours), Nursing Pharmacology Credit (9.25 hours), PA Patient Safety and Risk Credit (5.25 hours)

The 14th Annual Lung Cancer Symposium offers physicians, nurses, physician assistants, respiratory care specialists and public health professionals a comprehensive lung cancer update, and provide an interdisciplinary perspective of the disease, care and treatment management plans.

Keynote: Robert Timmerman MD, FASTRO, FACR

Dr. Robert Timmerman is Professor and Chair of the Department of Radiation Oncology, as well as Professor of Neurosurgery, and is the holder of the Effie Marie Cain Distinguished Chair in Cancer Therapy Research at UT Southwestern Medical Center.

One of Dr. Timmerman’s greatest successes was the development of a trial that demonstrated inoperable lung cancer patients treated with SAbR could have considerably higher tumor control than with conventional radiation while still mostly avoiding toxicity. This provided hope to a whole new class of patients – the elderly, those with multiple health conditions, and others – who previously faced poor odds of beating their cancer. His treatment method has now become the new standard of care for this class of patients.

Dr. Timmerman currently directs training courses in stereotactic radiotherapy both at UT Southwestern and nationally for members of the national Radiation Therapy Oncology Group. He is a highly sought-after guest speaker and has authored or co-authored numerous peer-reviewed articles and textbooks.

With his patients, he continues to focus on diseases of the central nervous system, including cancer of the brain and spine, as well as lung cancer. He also specializes in seeing children and young adults who are still growing – those for whom extremely precise treatment is likely to result in better long-term quality of life.

Keynote: Daniel H. Sterman, MD, FCCP, ATSF, DAABIP

Dr. Daniel Sterman specializes in interventional pulmonology, a field that combines pulmonary medicine and thoracic surgery to perform minimally invasive procedures for diagnosing and treating cancers of the chest. Clinical expertise includes lung cancer, malignant pleural mesothelioma, pleural effusion, and disorders of the large airways such as the trachea and bronchi. He also performs staging procedures to assess disease progression.

For more than 18 years, Dr. Sterman has led research in gene therapy and immunotherapy to control chest tumors and improve outcomes for patients with lung cancer and mesothelioma, advancing care through clinical trials and innovative therapies.

Keynote: Helena A. Yu, MD

Dr. Helena Yu is a board-certified medical oncologist specializing in the care of patients with lung cancer. As a thoracic medical oncologist, Dr. Yu focuses on cancers of the chest, including lung, tracheal (windpipe), and thymic (thymus) cancers.

In addition to her clinical expertise, Dr. Yu is an early drug development specialist—a physician-scientist dedicated to testing new therapies to improve cancer treatment. She has advanced training in designing and conducting clinical trials, which are research studies that evaluate innovative approaches to care.

---

Successful Completion
To successfully complete this activity, the required evaluation must be completed no later than Thursday, April 2, 2026. Thereafter, the evaluation will no longer be available and credits will not be issued. No refunds will be offered for failure to complete the required evaluation by the stated deadline.

1. Discuss new modalities of surgery which can lead to long-term cures and optimal results for patients with lung cancer.
2. Examine the utilization of a multidisciplinary team in the treatment of lung cancer.
3. Assess the evolving radiotherapy techniques in treatment of lung cancer.
4. Review the newest targeted molecular therapies and immunotherapies for lung cancer.
5. Explain state of the art of lung cancer prevention.
6. Evaluate the most appropriate diagnostic approach for lung nodules, lung masses, and metastatic lesions.
7. Recognize how treatment techniques vary based on lung cancer disease stage.
8. Assess the use of SBRT in early-stage lung cancer treatment.
9. Identify specific strategies to implement on lung cancer disease management as part of a continuing improvement process for clinical practices.
10. Employ lung cancer screening best practices for collaboration with multi-disciplinary teams to improve patient care.
11. Assess respiratory care treatment strategies for lung cancer patients.
12. Employ the latest community outreach strategies to reduce lung cancer disparities around the region.
13. Explain the role of sub-lobar versus lobar resection in treating lung cancer with surgical intervention.
14. Identify patients that are ideal candidates for minimally invasive, robotic surgery as a treatment for early-stage lung cancer.
15. Examine the role of education in pulmonary rehabilitation with lung cancer patients.
16. Practice multi-disciplinary collaboration with thoracic surgery, medical oncology, radiation oncology, and interventional pulmonology through a mock tumor board.
17. Apply relationship-building values and the principles of collaboration in caring for lung cancer patients.
18. Examine the role of artificial intelligence across the lung cancer care continuum.
19. Assess tobacco cessation strategies for patients across the lung cancer care continuum.
20. Compare evolving immunotherapy modalities for genetic mutations in lung cancer treatment.

Physician Nurse/Nurse Practitioner Physician Assistant Respiratory Therapist Social Worker/Case Manager/Public Health Other Healthcare Professional Resident/Fellow Trainee/Student Industry Professional	$279 $145 $145 $145 $145 $145 $100 $100 $500
SKCN Member	$100
Jefferson Enterprise Physician Nurse/Nurse Practitioner Physician Assistant Respiratory Therapist Social Worker/Case Manager/Public Health Other Healthcare Professional Resident/Fellow Trainee/Student	$0 $0 $0 $0 $0 $0 $0 $0

Modules
This activity offers optional pre-conference modules. The online pre-conference modules can be found on the Course Content tab. Credit count includes completion of all modules.

1. Community Engaged Research to Reduce Tobacco Use Disparities/Lilianna Phan, PhD, MPH, MS

2. Patient-Reported Outcomes in Lung Cancer Screening/Christopher Slatore, MD, MS

3. Role of Radiation Oncology in Early Detection of Lung Cancer/Erik Blomain, MD, PhD

4. Optimizing the Electronic Health Record to Improve Lung Cancer Screening Opportunities for Primary Care Populations/Bryan O’Connell, MD

5. Transforming Lung Cancer Screening Through Artificial Intelligence in Thoracic Radiology/Paras Lakhani, MD

6. Updates in Thoracic Surgery for Early-Stage Lung Cancer/Nathaniel R. Evans III, MD, FACS, FCCP

In support of improving patient care, Thomas Jefferson University is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians: This educational activity is designated for a maximum of 15.00 AMA PRA Category 1 Credits ^TM . Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses: This activity awards 15.00 nursing contact hours.

Physicians Assistants:

 

Thomas Jefferson University has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 15.00 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

 

Other Healthcare Professionals: This educational activity is designated for 15.00 AMA PRA Category 1 Credit ^TM. Participants should claim only the credit commensurate with the extent of their participation in the activity.

Respiratory Therapists: Application for credits pending

Agenda
Agenda subject to change without notice.

Cancellation Policy
Requests for refunds must be submitted in writing and received in the Office of CPD two weeks prior to the start date of the course. There will be no refunds after this period.*  Cancellations notified before the two week time frame will incur a 25% administration fee (with a minimum of $20).  Registrants who fail to attend the conference are responsible for the entire fee.  All refunds will be processed after the conference.  The University reserves the right to cancel or postpone this course due to unforeseen circumstances.  In the event of cancellation or postponement, the University will refund registration fees, but is not responsible for related costs or expenses to participants, including cancellation fees assessed by hotels, airlines or travel agencies.  Email [email protected] - please include the activity name in the subject line.
Registration fees will be refunded less a 15% administration fee to international conference registrants who are unable to secure a travel visa. Registrants must provide proof of visa denial. 

Jefferson Release Policy
Jefferson may record/livestream/photograph this educational activity. These images/recordings, along with your name, may be used in Jefferson publications or on the Jefferson website. If you verbally submit any questions for Q&A sessions, you are agreeing to be recorded and to have that recording available in enduring materials. Once photographed, filmed, recorded, or videotaped, you waive the right of inspection or approval to which such images/recordings may be put and Jefferson has the right to use, publish, reproduce, modify, adapt, and distribute at any time in any manner or medium.

Jefferson HIPAA Policy
As an attendee of this educational activity hosted by Thomas Jefferson University, Jefferson University Physicians, and Thomas Jefferson University Hospitals, Inc. (collectively 'Jefferson'), you may gain access to certain proprietary information ('Confidential Information'), including Protected Health Information ('PHI').

By participating in this educational activity, you agree to maintain the confidentiality of all Confidential Information, including all PHI, obtained from any source. You also agree to take all necessary steps to protect such Confidential Information and shall not directly or indirectly disclose or use it in any manner or for any reason, other than as necessary to complete the educational activity. Further, you agree not to take photographs, record in any manner or otherwise reproduce any such Confidential Information. You understand that any unauthorized use or disclosure of Confidential Information may result in possible legal action against you by Jefferson whose confidentiality is breached.

Photography and Recording
Unauthorized recording or photography at a Jefferson-sponsored event is strictly prohibited. Individuals found violating this policy will be asked to vacate the activity. No credits or refund will be issued.

Copyright
All rights reserved – Thomas Jefferson University. No part of this program may be used, reproduced, or shared in any manner whatsoever without express written permission, except in the case of brief quotations embodied in articles or reviews.

You are not logged in.

Please click the button below to login or create a new account before continuing.

The Warwick Hotel Rittenhouse Square Philadelphia
220 S 17^th Street
Philadelphia, PA 19103

Click HERE to book a room

 Directions

Other Nearby Accommodations
Fairfield Inn & Suites by Marriott Downtown/Center City
261 S 13th Street
Philadelphia, PA 19107 

Mitigation of Relevant Financial Relationships

Thomas Jefferson University adheres to the Standards for Integrity and Independence in Accredited Continuing Education and the policies that supplement the Standards.

All planners, faculty, and others in control of educational content are required to disclose any relevant financial relationships with ACCME defined ineligible companies within the past 24 months. Any conflicts of interests have been mitigated prior to this educational activity. Such disclosures will be available prior to the start of the activity. Jefferson conflict of interest mitigation process may result in changes to the program agenda.

Off-Label/Investigational Use
All faculty/presenters/authors at Thomas Jefferson University sponsored events are required to disclose whether or not their content contains information of commercial products/devices that are unlabeled for use or investigational uses of products not yet approved. Product(s) is/are not included in the labeling approved by the U.S. FDA for the treatment of disease(s).

Content Disclaimer
The views expressed in this activity are those of the faculty. It should not be inferred or assumed that they are expressing the views of any manufacturer of pharmaceuticals or devices or Thomas Jefferson University.

It should be noted that the recommendations made herein with regard to the use of therapeutic agents, varying disease states, and assessments of risk, are based upon a combination of clinical trials, current guidelines, and the clinical practice experience of the participating presenters. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult all available data on products and procedures before using them in clinical practice.

Exhibitor Rules

• Exhibitor is not providing commercial support for this educational activity. Exhibitor is purchasing exhibit space.

• Exhibits are intended for informational purposes, products should not be sold through the exhibit hall.

• TJU and the exhibitor acknowledge and agree that the exhibitor may be subject to Section 6002 of the Affordable Care Act, which added Section 1128G to the Social Security Act, and its implementing regulations codified in 42 CFR 402 &403 (Collectively the Sunshine Act). Exhibiting companies are solely responsible for collecting any information about actions within their virtual exhibit space that constitutes a payment or transfer of value to a covered participant, which is required to reported under the Sunshine Act.

• Exhibitors may observe educational sessions but must refrain from participating in the activity.

• No recordings of the scientific sessions on behalf of the exhibitor's company is permitted.

Application Deadline
Applications for exhibits will be accepted through Friday, February 27, 2026. After February 27, 2026, applications may be accepted on a case by case basis.

Cancellation and Refunds
In the event that the symposium is canceled by the organizers, exhibit fees will be refunded in full, however Thomas Jefferson University is not responsible for other expenses incurred by the exhibitor.

In the event an exhibitor cancels participation, refunds will be made as follows:

• Prior to the deadline of February 27, 2026 a refund will be given minus a 10% administration fee.

• After February 27, 2026 no refund will be given.

• Exhibitors who are absent from the conference will not receive a refund.

• Exhibit cancellations must be made in writing.

Send cancellation notice to [email protected] and include name of activity in subject line. 

Exhibit at this Event